Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Reynolds

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Lancet. Oncology|November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trialEdward S Kim, Marcus Neubauer, Allen Cohn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)David R Spigel, Craig Reynolds, David Waterhouse, et al.
The Oncologist|September 3, 2015
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based RecommendationsBenjamin P Levy, Marc D Chioda, Dana Herndon, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2018
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153David Waterhouse, Leora Horn, Craig Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancerCraig Reynolds, Coleman Obasaju, Michael J Schell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyNasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Lancet. Oncology|November 16, 2013
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trialEdward S Kim, Marcus Neubauer, Allen Cohn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2018
Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)David R Spigel, Craig Reynolds, David Waterhouse, et al.
The Oncologist|September 3, 2015
Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based RecommendationsBenjamin P Levy, Marc D Chioda, Dana Herndon, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2018
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153David Waterhouse, Leora Horn, Craig Reynolds, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancerCraig Reynolds, Coleman Obasaju, Michael J Schell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. OncologyNasser Hanna, Marcus Neubauer, Constantin Yiannoutsos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2020
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153David M Waterhouse, Edward B Garon, Jason Chandler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Pageof 2